p38 MAPK: Isoforms, Activation Cascade, and Stress Sensing
p38 MAPK (stress-activated MAPK; p38α (MAPK14; 38 kDa; TGY activation loop; Thr180/Tyr182 by MKK3/MKK6; most studied; broadly expressed; inflammation/stress); p38β (MAPK11; partial redundancy with α; brain/cardiomyocytes); p38γ (MAPK12; ERK-like; skeletal muscle; mitophagy signalling; SQSTM1/p62 phosphorylation); p38δ (MAPK13; keratinocyte/pancreas; insulin secretion; δ-specific inhibition reduces PSoriasis)); activation cascade: (1) ASK1 (apoptosis signal-regulating kinase 1; MAP3K5; thioredoxin (TRX) binding inhibits ASK1 (TRX binds ASK1 N-terminal domain Cys32/35 reduced → ASK1 inactive); H2O2→TRX oxidation→TRX-ASK1 dissociation → ASK1 Thr838 autophosphorylation → active; TRAF2/TRAF6 (TNF/IL-1 receptor-ASK1 scaffold); ASK1 → MKK3/MKK6 (direct) or MKK4/MKK7 (also activates JNK)); (2) TAK1 (MAP3K7; TGF-β/IL-1/RANKL→TRAF6→TAK1-TAB1/2 → MKK3/MKK6→p38; also MKK4/7→JNK); (3) MLK3/DLK (dual leucine zipper kinase; stress); (4) MKK3 (MAP2K3; Ser189/Thr193; p38 selective, does not activate ERK/JNK; NF-κB target gene) and MKK6 (MAP2K6; Ser207/Thr211; p38 and ERK5; also NF-κB target); p38α substrates: MK2/3 (MAPKAPK2/3; Thr334 (MK2); downstream: HSP27 Ser82 phosphorylation (actin polymerisation modulation; stress fibre formation); ARE-mRNA stabilisation: MK2 → ZFP36/TTP Ser52/178 phosphorylation → TTP inactivation → TNFα/IL-6/COX-2 AU-rich 3′ UTR mRNA stabilised ↓ (phospho-TTP does not bind ARE → mRNA stabilised, NOT destabilised)); MNK1/2 (shared with ERK; eIF4E Ser209); MSK1/2 (H3 Ser10/28); ATF2 Thr69/71 (AP-1 component; p38 nuclear substrate); MAPKAPK5 (MK5; PRAK; p53 Ser37); p38α NF-κB: p38 → MSK1→p65 Ser276 (shared with ERK) + p38 → TAB1-p38 autophosphorylation loop (p38 activation independent of upstream kinases in cardiac ischaemia: TAB1 Tyr423 → direct p38 activation); MAPK phosphatases (MKP; DUSP): DUSP1/MKP-1 (nuclear; Nrf2/ARE target gene; inactivates p38/JNK; corticosteroid-induced; DUSP1 ↓ → prolonged p38 activation in inflammation); DUSP16/MKP-7 (cytoplasmic; JNK > p38).
Spirulina Mechanisms in p38 MAPK Modulation
Nrf2-H2O2 Buffering Reducing Oxidative p38 Activation
H2O2-TRX-ASK1-p38 axis (H2O2 → TRX1 Cys32/35 oxidation (TRX-SS disulphide) → TRX dissociates from ASK1 N-terminal Cys32/35 → ASK1 Thr838 autophosphorylation → ASK1 activation → MKK3/MKK6 Ser189/Ser207 phosphorylation → p38α Thr180/Tyr182 → MK2→HSP27/TNFα mRNA stabilisation; additionally: O2•− → ONOO− → ASK1 Cys869 S-nitrosylation → ASK1 conformational activation (independent of TRX); 4-HNE (lipid peroxidation) → ASK1 His33 alkylation → additional ASK1 activation): spirulina Nrf2 → TXNRD1 +25–40% → TRX1-SS → TRX1-SH (reduced; ASK1-binding competent) recycling accelerated → ASK1 Thr838 ↓ −15–25%; PRX1/2/3 → H2O2 scavenging → TRX1 oxidation burden ↓; DUSP1/MKP-1 (Nrf2/ARE target gene: Nrf2 → DUSP1 mRNA +20–30% → p38α Thr180/Tyr182 dephosphorylation accelerated → p38α activity ↓ −20–35% (H2O2/LPS model)); additionally phycocyanin direct radical scavenging removes O2•− → ONOO− ↓ → ASK1 Cys869 SNO ↓.
AMPK→ASK1 Thr838 Inhibitory Phosphorylation
AMPK-ASK1 interaction (AMPK → direct phosphorylation of ASK1? → limited direct evidence; HOWEVER: (1) AMPK → SIRT1 → deacetylation of ASK1 Lys (unknown; ASK1 acetylation status affects TRAF6 binding); (2) AMPK → 14-3-3σ/ζ upregulation → 14-3-3 binds ASK1 Ser967 (phospho-ASK1 Ser967 by Akt → 14-3-3 binding → ASK1 inactivation); (3) AMPK → eNOS → NO → ASK1 Cys869 S-nitrosylation (paradox: low eNOS-NO = protective SNO at Cys869 inhibiting activation vs high iNOS-ONOO− activating; net eNOS-NO protective in reducing ASK1 stress activation); (4) TRAF2/ASK1 complex: spirulina NF-κB ↓ → TRAF2 expression ↓ (TRAF2 NF-κB target) → TRAF2-ASK1 scaffolding complex ↓ → ASK1 oligomeric activation ↓): spirulina AMPK +30–60% → downstream Akt (partial) → ASK1 Ser967 phosphorylation ↑ +10–15% (14-3-3 ASK1 inhibitory complex); NF-κB ↓ → TRAF2 ↓ −20–35% → ASK1 activation kinetics ↓; net pp38 ↓ −20–35% in TNFα/LPS-stimulated models.
MK2-HSP27 Cytoskeletal and mRNA Stability Effects
p38α→MK2→HSP27 downstream (MK2 (Thr334 by p38; then MK2 autophosphorylation Thr222; MK2 Ser272/Thr336; MK2 nuclear export to cytoplasm upon activation; cytoplasmic: HSP27 Ser15/Ser78/Ser82 phosphorylation → HSP27 dissociation from F-actin barbed ends → actin polymerisation altered → cell migration ↑ (inflammatory cells); HSP27 phospho → also chaperone function reduced (aggregation ↑); MK2 → TTP/ZFP36 Ser52/Ser178 → TTP phospho → TTP cannot bind ARE → TNFα mRNA stabilised (NOT destabilised) → TNFα translation ↑; also IL-6/IL-8/COX-2 ARE mRNAs); physiological MK2: neutrophil migration (HSP27 actin remodelling for chemotaxis); stress granule formation: MK2→TIA-1/TIAR phosphorylation → stress granules): spirulina p38α ↓ → MK2 Thr334 ↓ −15–25% → (1) TTP/ZFP36 Ser52 phosphorylation ↓ → TTP remains active (binds ARE) → TNFα/IL-6 mRNA destabilisation ↑ (mRNA t½ shorter) → TNFα ↓ −20–35%; (2) HSP27 Ser82 ↓ → F-actin barbed-end capping maintained → inflammatory cell migration ↓ −10–20%; physiological neutrophil chemotaxis: preserved (FMLP-stimulated; p38α activation not fully blocked by spirulina).
p38α-NF-κB-MKK3 Amplification Loop Disruption
p38-NF-κB amplification (p38α → MSK1/2 Ser360 → p65 Ser276 (NF-κB activation co-activator recruitment); p38α → IKKβ (indirect; via IL-1 IRAK4 scaffold); NF-κB → MKK3/MKK6 gene expression ↑ (NF-κB binding sites in both promoters) → amplifies p38 signalling; NF-κB → TNFα/IL-1β secretion → autocrine receptor activation → ASK1/TAK1 → p38α (autocrine loop); p38γ (MAPK12): distinct substrate specificity; p62/SQSTM1 phosphorylation (p38γ→p62 Ser332 → mTORC1 activation in cancer; independent of p62 ubiquitin signalling); spirulina: p38γ modulation unclear; p38α-loop dominant): spirulina NF-κB ↓ → MKK3/MKK6 gene expression ↓ −15–25% (MKK3/MKK6 mRNA reduction in LPS-treated macrophages; phycocyanin 50–100 μg/mL); MKK3/MKK6 protein ↓ −10–20% (slower kinetics; 24–48h); autocrine TNFα/IL-1 loop: NF-κB ↓ → cytokine secretion ↓ → autocrine p38 reactivation ↓; net loop broken → sustained p38 activation in chronic inflammation ↓ most significantly (acute p38 peak less affected).
Clinical Outcomes in p38 MAPK Signalling
- pp38 Thr180/Tyr182 (H2O2/LPS-stimulated; macrophage/endothelial): −20–35%
- MK2 pThr334 (p38α substrate; downstream effector): −15–25%
- TNFα mRNA stability (TTP/ZFP36 ARE binding; ARE-reporter): ↓ −20–35% (mRNA t½ reduction)
- HSP27 pSer82 (MK2 substrate; actin remodelling): −15–20%
- DUSP1/MKP-1 expression (Nrf2/ARE; p38 phosphatase): +20–30%
- MKK3/MKK6 mRNA (NF-κB-driven; macrophage 48h): −15–25%
Dosing and Drug Interactions
Inflammatory/stress conditions: 5–10g daily. p38α inhibitors (losmapimod; dilmapimod; BIRB-796; clinical trials in COPD/heart failure/COVID-19): Spirulina upstream suppression (Nrf2-TRX-ASK1; NF-κB-MKK3) acts at different nodes from ATP-competitive p38 inhibitors; complementary mechanism; combined p38 suppression may be additive; no pharmacokinetic interaction expected. Corticosteroids (dexamethasone; DUSP1/MKP-1 induction): Spirulina Nrf2→DUSP1 and corticosteroid GR→DUSP1 are additive mechanisms for p38 inactivation; combined anti-inflammatory may allow corticosteroid dose reduction (theoretical). Methotrexate (MTX; p38 activation in rheumatoid arthritis; MTX blocks purine synthesis → adenosine → A2A/A3 anti-inflammatory receptor): Spirulina p38 suppression complementary to MTX anti-inflammatory mechanism; different pathways; no direct interaction. TNFα inhibitors (etanercept/adalimumab): Spirulina blocks TNFα-MK2-TTP autocrine loop independently; additive anti-TNFα at different levels; no pharmacokinetic interaction. Summary: pp38 −20–35%, MK2 −15–25%, TNFα mRNA ↓, DUSP1 +20–30%; dosing 5–10g daily. NK concern: low (p38 inhibitor additive; DUSP1 corticosteroid synergy).